A randomized, non-inferiority phase III clinical trial of immunogenicity and safety of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10–60 Authors: Danhua Zhao, Junshi Zhao, Xiaopan Chen, Lingfeng Yuan, Ping Wang, Leitai Shi, Yunpeng Wang, Jia Li, Lijuan Zhou, Xiaohong Wu, Shilong Yang, Lidong Gao Published: 2025 ABSTRACT AbstractBackgroundThis study aimed to evaluate the safety and immunogenicity of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10–60MethodsThis study adopts a randomized, double-masked, single-center, non-inferiority trial design with similar vaccines. This phase III clinical trial consisted of two stages, the first stage recruited 80 participants, and the second stage recruited 1,800 participants. In stage 1, 40 participants aged 18–60 years were enrolled to vaccinate with the investigational vaccine firstly, and then 40 people aged 10–17 years were enrolled for safety analysis. The number of participants who received either a 5-dose or a 4-dose immunization regimen was 40. During stage 2, subjects were assigned to 5-dose Essen group, 4-dose Zagreb group, 5-dose control group to conduct rabies virus neutralization antibody detection and adverse events(AEs) collection.ResultsIn stage 2, 14 days after the initial dose of immunization and 14 days after completing the immunization program, the differences in the seroconversion rates (5-dose Essen group vs. 5-dose control group, 4-dose Zagreb group vs. 5-dose control group) were both 0.00, with the lower limits of the 95% confidence intervals exceeding the non-inferiority margin of −5%. AEs occurred at a total rate of 35.17% in the 5-dose Essen group, 36.50% in the 5-dose control group, and 30.00% in the 4-dose Zagreb group.ConclusionsThe immunogenicity of 5-dose and 4-dose schedules of the freeze-dried human rabies vaccine (MRC-5 cells) was non-inferior to that of the human diploid cell vaccine, and the safety was good after vaccination.Trials registrationNCT06078423, A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells), “retrospectively registered” on 2023–10-11.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12075-y.Keywords: Freeze-dried human vaccine, Rabies vaccine, MRC-5 cells, Immunogenicity, Safety, Positive control, Clinical trial Introduction Rabies is an extremely fatal communicable disease caused by the rabies virus [1]. This virus is primarily spread by infected animals biting, scratching, or licking at torn skin or mucous membranes. Once the virus invades the central nervous system, the case fatality rate approaches 100% [2, 3]. Approximately 35,000 to 50,000 people die from rabies annually, with the vast majority occurring in rural areas of Africa and Asia [4, 5]. In contrast, human rabies has been largely eliminated in industrialized countries and many urban areas of Latin America, largely through dog vaccination and other control programs [6]. This disparity underscores the ongoing need for accessible and effective rabies vaccines, particularly in resource-limited settings [2, 7]. Currently, according to the different cell matrices required for virus culture, the existing mainstream rabies vaccines in the world can be divided into two categories: human diploid cell vaccines (HDCVs) and animal cell vaccines-the latter produced using primary cells such as hamster kidney or chicken embryo fibroblasts, or continuous cell lines such as Vero cells [7–11]. HDCVs are cultured in human diploid cells (e.g., WI-38, MRC-5) and offer advantages such as the absence of tumorigenic DNA risks or exogenous protein allergens, along with favorable immunogenicity and memory responses [12, 13]. Since 1974, HDCVs have already been recommended as the gold standard by the World Health Organization [14]. However, due to the high difficulty of its culture technology, the relatively low reproduction titer of the virus and the complex production process, the HDCVs are costly and expensive, which limits their widespread use in developing countries [15]. At present, only two manufacturers-Chengdu Kanghua Biological Products Co., Ltd. and Beijing Minhai Biotechnology Co., Ltd.-supply HDCVs in China. The Kanghua inactivated HDCV, the first human diploid cell rabies vaccine approved in China, is licensed for a 5-dose Essen regimen (days 0, 3, 7, 14, and 28). Its Phase III trial also demonstrated good safety and immunogenicity under a 4-dose Zagreb regimen (two doses on day 0, one each on days 7 and 21) in participants aged 10–60 years [16, 17]. Therefore, it serves as a relevant and high-quality comparator in clinical evaluations. The investigational vaccine in this trial is a purified, inactivated rabies virus propagated in MRC-5 cells, developed as a novel lyophilized HDCV by Anhui Zhifei Longcom Biopharmaceutical. Previous Phase I and II trials have established its preliminary safety, tolerability, and immunogenicity in healthy adults, supporting its advancement to this confirmatory Phase III study. The present study aims to evaluate the immunogenicity and safety of this new HDCV in comparison with the licensed Kanghua HDCV, using both the 5-dose Essen and the 4-dose Zagreb regimens in participants aged 10–60 years. Methods Study design and participants This randomized, double-masked, non-inferiority trial was carried out at the Hunan Provincial Center for Disease Control and Prevention (China) with consent from the Ethics Committee. Participants were fully briefed on the trial details prior to their enrollment in the trial, and an informed consent form was signed by each participant. For further information, please refer to the Declarations section. The individuals in 10–60 years included in this trial was healthy. Key exclusion criteria encompassed: prior rabies immunization or significant animal injury; recent receipt of blood products, vaccines, or investigational drugs; immunodeficiencies or immunosuppression; relevant neurological/psychiatric history; any history of severe allergy or adverse reactions to vaccines; acute illness or uncontrolled chronic conditions (e.g., hypertension, asthma); and pregnancy or lactation. In order to conduct a safety investigation, 40 volunteers, aged 18 to 60, were randomized to receive the investigational freeze-dried human rabies vaccine (MRC-5 cells) in either the 5-dose Essen schedule (given on days 0, 3, 7, 14, and 28) or the 4-dose Zagreb schedule (two doses on day 0, followed dy one dose on day 7 and 21) in stage 1. If the incidence of grade 3 adverse reactions(ARs) after any dose of vaccination within 7 days was less than 15% in stage 1 of the trial, another 40 cases from the 10–17 age group would be enrolled following the same procedure. If the frequency of ARs of Grade 3 in 80 subjects was less than 15%, and no vaccine-related serious adverse events(SAEs) occurred, stage 2 was implemented. In stage 2, a total of 1,800 participants aged 10–60 were recruited and randomly allocated to the 5-dose (given on days 0, 3, 7, 14 and 28) Essen group, 4-dose (two doses on day 0, followed dy one dose on day 7 and 21) Zagreb group and 5-dose (given on days 0, 3, 7, 14 and 28) control group in a 1:1:1 ratio (Fig. 1). To evaluate immunogenicity, blood samples were collected from each participant at five distinct time points: prior to the first vaccination dose, 7 days post-first dose, 14 days post-first dose, 14 days and 3 months after completing the full vaccination regimen- A full course of immunization was defined as the completion of all scheduled doses according to the respective regimen. Additionally, participants in the experimental groups (Essen and Zagreb grops) underwent an extra blood sample collection 12 months after the full vaccination course for further immune persistence evaluation (Fig. 1). All participants were monitored for safety up to 6 months following the completion of the vaccination regimen. Study overview in stage 2. Schematic overview of the study groups and their corresponding study procedures. Blood was drawn pre-vaccination. 35 day/42 day represented 14 days after the completion of the vaccination course; 3 month and 12 month denoted 3 months and 12 months after full vaccination, respectively Vaccine The freeze-dried human rabies vaccine (MRC-5 cells) served as the investigational vaccine, manufactured by Anhui Zhifei Longcoma Biopharmaceutical Co. Ltd. (Batch No.: 20180902). The active comparator was a licensed freeze-dried human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd., Batch No.: 20171221). Both vaccines were presented as freeze-dried powder injections. After being reconstituted, each 1.0 mL dose was given as an intramuscular injection in the upper arm’s deltoid muscle. Randomization and masking An independent randomization statistician generated the allocation sequence using SAS software (v9.4) with a permuted block design. In stage 2, eligible participants were randomly allocated at a 1:1:1 ratio to three groups: the 5-dose Essen group receiving the investigational vaccine, the 4-dose Zagreb group administered the investigational vaccine, or the 5-dose control group receiving the licensed vaccine. Each participant was assigned a study number in the order of screening and received the investigational product corresponding to their number. A two-stage masking strategy was implemented. The stage 1 was open-label. During the stage 2, masking was applied only to the 5-dose program (Essen and control groups). To ensure masking, the investigational vaccine and the active comparator were identical in appearance (label, and lyophilized cake) and were packaged indistinguishably. A unique randomization code, generated by an independent biostatistician not involved in the trial, linked each kit number to a treatment group. Protocol-specified guidelines authorized the responsible site investigator to perform an individual emergency unblinding in the following two scenarios: 1) occurrence of a SAE where urgent clinical decision-making required knowledge of the study vaccine; or 2) a new animal exposure incident requiring post-exposure prophylaxis. In either case, unblinding was to be carried out strictly according to the procedure of opening the emergency code-break envelope. The masking in this study was maintained until the completion of the 6-month observation period following the full vaccination course. Subsequently, a two-stage unblinding procedure was then followed: primary unblinding after database lock revealed group allocations (e.g., A, B, C) without specifying the vaccine type for initial statistical analysis; secondary unblinding subsequently identified the specific vaccine (investigational or control) for each group. All unblinding actions were formally documented. The 4-dose Zagreb group was unblinded to the investigators and participants because its distinct immunization and phlebotomy schedules made masking impractical. Immunogenicity and immune persistence assessment In line with the predefined grouping, approximately 3.0 mL of venous blood was drawn from subjects at each scheduled blood collection time. The serum was subsequently separated and divided into two samples: one for testing (at least 0.5 mL) and the other as a reserve, stored at −20 °C or lower. All serum specimens were systematically transferred to the National Institute for Food and Drug Control for rabies virus neutralizing antibody quantification. Antibody titers were quantitatively assessed using the Rapid Fluorescence Focus Inhibition Test (RFFIT), with seropositivity defined as achieving a neutralizing antibody concentration ≥0.5 IU/mL per WHO immunological criteria. The RFFIT methodology is outlined in the Supplementary Methods. The primary immunogenicity endpoints were the antibody seroconversion rate and geometric mean concentration (GMC), assessed 14 days post-first dose and post-full vaccination across all groups. Non-inferiority was defined as the lower bound of the 95% CI for the seroconversion rate difference (experimental - control) exceeding −5%, and simultaneously, the lower bound of the 95% CI for the GMC ratio (experimental/control) exceeding 0.67, for each comparison against the 5-dose control group. Secondary endpoints comprised the antibody seroconversion rate and GMC measured in all three groups 7 days after the first dose. For the assessment of immune persistence, the antibody positive rate and GMC were analyzed in all three groups at 3 months post-complete vaccination. Additionally, these immunogenicity parameters were evaluated for two experimental groups (Essen and Zagreb) at 12 months following the full immunization course. Safety assessment All subjects who received at least one dose of the vaccine will be included in the safety analysis set. The trial protocol mandated systematic AEs documentation through dual monitoring phases: immediate surveillance during the 30-minute post-vaccination observation period and active solicitation of vaccine-related reactions during Days 0–7 follow-up. Monitored parameters included both local injection site reactions (pain, induration, erythema, edema, pruritus, cutaneous eruptions) and systemic manifestations (asthenia, hypersensitivity reactions, cephalgia, emesis, myalgia, nausea, diarrheal episodes, and arthralgia). This study also collected unsolicited AEs (e.g., neurological diseases, respiratory system, thoracic and mediastinal diseases, gastrointestinal system diseases and musculoskeletal manifestations) by combining participant-initiated reporting and investigator-driven scheduled assessments. During the 6-month follow-up phase after the initial dose, all SAEs were additionally recorded. The classification and grading of both systemic and localized post-vaccination ARs were rigorously implemented in accordance with the National Medical Products Administration (NMPA) Technical Guidelines for Adverse Reaction Classification Criteria in Preventive Vaccine Clinical Trials [18]. Statistical analysis The sample size calculation was based on a one-sided significance level of 0.025 and a statistical power of 85%. A total of 366 participants per group (1,098 overall) were required to demonstrate non-inferiority. To account for regulatory safety requirements and potential dropouts, the planned enrollment was expanded to 600 participants per group, totaling 1,800 participants in Stage 2. A fixed-sequence hierarchical testing procedure was employed to control the Type I error rate. Non-inferiority of the 5-dose experimental group versus the control group was tested first on the primary endpoints (seroconversion rate and GMC at Day 14 post-first dose). Only if non-inferiority was established for the 5-dose group would the 4-dose experimental group then be tested against the control group on the same endpoints. For immunogenicity analysis, confidence intervals for proportions were calculated using the Clopper-Pearson method. Categorical variables were compared using the Chi-square or Fisher’s exact test, and continuous variables were analyzed using the t-test. Safety data, being primarily categorical, were compared between groups using Fisher’s exact test. Statistical analysis data set (1) Full Analysis Set (FAS): Included all randomized participants who received at least one vaccine dose and had valid pre-vaccination antibody results. (2) Per Protocol Set 1 (PPS1): Included FAS participants who complied with the protocol, received the initial doses (first two doses in the 5-dose regimen or first dose in the 4-dose regimen), and had valid antibody data from pre-vaccination and 7 days post-first dose. (3) Per Protocol Set 2 (PPS2): Included FAS participants who complied with the protocol, received the initial series (first three doses in the 5-dose regimen or first two doses in the 4-dose regimen), and had valid antibody data from pre-vaccination and 14 days post-first dose. (4) Per Protocol Set 3 (PPS3): Included FAS participants who completed the full vaccination course and had valid antibody data from pre-vaccination and 14 days post-full vaccination. (5)Immune Persistence Set 3(IPS3): Included participants from the experimental groups who completed the full course, provided a blood sample 3 months later, and had valid antibody data for 3-month immune persistence analysis. (6)Immune Persistence Set 12(IPS12): Included participants from the experimental groups who completed the full course, provided a blood sample 12 months later, and had valid antibody data for 12-month immune persistence analysis. (7)Safety Set (SS): Included all participants who received at least one vaccine dose. Analysis was based on the actual vaccine received. Results Demographic and baseline profiles In this study, the first subject was enrolled on October 19, 2019, and the follow-up of the last subject was completed on August 30, 2021. In stage 1, 79 volunteers aged 10–60 received their first dose of the vaccine. The specific groupings are as follows: 39 participants belonged to the 5-dose Essen group (which included one unvaccinated subject), and the other 40 participants belonged to the 4-dose Zagreb group. In stage 2, a total of 1,800 subjects were recruited for this study, including 600 in each group. Figure 2 offers a comprehensive overview of the process by which individuals were eliminated in stage 2. Flow diagram of the stage 2.The number of subjects who provided baseline blood samples (pre-vaccination) was identical across the three groups and matched the number receiving the first vaccine dose. In the Essen and control groups, the number of participants providing samples at 7 and 14 days after the first dose corresponded to the numbers sampled after the third and fourth doses, respectively. D35/D42 represented 14 days after the completion of the vaccination course; M3 and M12 denoted 3 months and 12 months after full vaccination, respectively The demographic distributions of the stage 1 and the stage 2 are roughly similar. The age, gender, ethnicity, height, and weight of the participants in three groups were evenly distributed (Table 1). Table 1Comparison of demographic and baseline characteristics in stage 2Characterizers5-dose Essen group5-dose control group4-dose Zagreb groupP valueAge, years, n(%)0.3239Mean (SD)39.51 (12.13)38.64 (12.39)38.54 (12.49)Median40.8140.5039.87Min, Max10.2, 59.810.1, 59.610.1, 60.6Sex, n(%)0.0917Male241 (40.17)205 (34.17)229 (38.17)Female359 (59.83)395 (65.83)371 (61.83)Ethnicity, n(%)0.4046Han Chinese597 (99.50)598 (99.67)596 (99.33)Yao Chinese0 (0.00)1 (0.17)2 (0.33)Tujia Chinese0 (0.00)1 (0.17)1 (0.17)Others3 (0.50)0 (0.00)1 (0.17)Height, (cm)0.4017Mean (SD)159.5 (8.5)159.1 (8.4)159.7 (8.6)Median159.0158.0159.0Min, Max130, 181120, 182130, 184Weight, (kg)0.8642Mean (SD)60.06 (11.65)59.78 (11.85)60.12 (12.03)Median59.0058.6558.00Min, Max25.5, 96.524.5, 105.221.5, 120.0Data are n (%), mean (SD), or Median and range. unless otherwise stated. Each group had 600 subjects. Percentages might not sum to 100 as a result of rounding Comparison of demographic and baseline characteristics in stage 2 Data are n (%), mean (SD), or Median and range. unless otherwise stated. Each group had 600 subjects. Percentages might not sum to 100 as a result of rounding Immunogenicity The analysis of immunogenicity was grounded in the detection of antibody titers via RFFIT. Among the enrolled subjects, 5% (90/1800) had a positive concentration of anti-rabies virus neutralizing antibodies before immunization, detailed in Table S1-3 in the Supplementary Material 1. In accordance with the NMPAs “Technical Guidelines for Clinical Research of Human Rabies Vaccines (Trial)”, the primary immunogenicity analysis was performed on the baseline seronegative population [19]. The 4-dose Zagreb group was found to have a higher GMC of neutralizing antibodies than the other two groups at day 7 after the first dose. This indicates that a quicker antibody response could be induced by primary two-dose series of the investigational vaccine. By day 14 following the first dose, the GMCs in the Essen, the Zagreb and the control groups were 32.50 IU/mL (30.48–34.65) and 32.71 IU/mL (32.18 - 36.46), 32.72 IU/mL (30.58–35.00), respectively, representing increases of 436.48-, 431.76- and 433.02-fold from pre-immunization levels; The GMC ratios (the Essen group/the control group, the Zagreb group/the control group) were 0.99(0.91–1.09)and 1.01(0.92–1.10). Day 14 following the full immunization course, the GMCs of the Essen, the Zagreb and the control group were 26.74 IU/mL (24.78–28.86) and 26.04 IU/mL (24.22–28.01), 25.84 IU/mL (23.93–27.90); The antibody GMC ratios (the Essen group/the control group, the Zagreb group/the control group) were 1.04(0.93–1.15), 1.01(0.91–1.12). The lower limit of 95% CI was greater than 0.67 (2/3)(Fig. 3: A and B). Immunogenicity analysis in seronegative participants. GMC (A), GMC ratio (B), SCR (C), difference in SCR (D). SCR = seroconversion rate; D7 = 7 days after the first vaccination; D14 = 14 days after the first vaccination; D35/D42 = 14 days after the completion of the vaccination course. Baseline was defined before the first vaccination. Seroconversion was defined as a ≥ 4-fold titer rise or seroconversion from negative to positive (≥0.5 IU/mL). Error bars indicate 95% CIs (GMC/GMC ratio: t-distribution/ANCOVA/ANOVA; SCR: Clopper-Pearson; SCR difference: Miettinen-Nurminen) At 14 days following the initial immunization dose, the seroneutralizing antibody seroconversion rates in the Essen, the Zagreb, and the control group were all 100%, which were consistent with those 14 days after the full immunization course. Day 14 after the first dose of immunization, the difference in the seroconversion rate between the Essen group and the control group was 0.00% (−0.70%-0.71%), and the result was 0.00% (−0.72%-0.72%) on day 14 after the full immunization course. Similarly, the differences in the seroconversion rate between the Zagreb and the control group were 0.00% (−0.70%-0.71%) and 0.00% (−0.71%-0.2%), respectively. All 95% confidence intervals had lower limits greater than −5%.(Fig. 3: C and D).Consistent with the total population, similar immunogenicity outcomes were observed in both the adolescent and adult subgroups when analyzed separately. Detailed data are provided in the Supplementary Material Table S4–S9. Immune persistence Seropositivity rates and GMCs at three months after full immunization, as determined by the IPS3 assay, are summarized as follows (Fig. 4). The Essen group demonstrated a seropositivity rate of 98.26% (96.83%-99.16%) with a GMC of 3.30 IU/mL (3.04–3.59). The control group showed a seropositivity rate of 97.36% (95.69%-98.52%) and a GMC of 3.32 IU/mL (3.04–3.61). The Zagreb group had a seropositivity rate of 98.42% (97.03%-99.28%) with a GMC of 2.87 IU/mL (2.66–3.10). Comparative analysis revealed no significant differences in seropositivity or GMC between the Essen and control groups (p = 0.2974 and p = 0.9519, respectively). Similarly, the seropositivity rate did not differ significantly between the Zagreb and control groups (p = 0.8320). However, the GMC in the Zagreb group was statistically significantly lower than that in the control group (p = 0.0151). Immune persistence analysis. SPR = Seropositivity rates; M3 and M12 denoted 3 months and 12 months after full vaccination, respectively Based on the IPS12 assay, the seropositivity rates at 12 months after the full immunization course were comparable between the 4-dose and 5-dose experimental groups, with values of 88.35% (85.31–90.95) and 88.45% (85.41–91.05), respectively. The GMCs were 1.30 IU/mL (1.19–1.42) in the 4-dose group and 1.42 IU/mL (1.29–1.55) in the 5-dose group. No statistically significant differences were observed between the two groups in either seropositivity rate (p = 0.9590) or GMC (p = 0.1929). Safety In stage 1, the participants exhibited good tolerance to two different investigational vaccination regimens (Table 2). The AEs at the vaccination sites of 5-dose and 4-dose regimens were mainly pain, with occurrence rates of 17.95% and 27.50% respectively. The systemic reactions were mainly fever, with incidence rates of 10.26% and 15.00% respectively. Age-stratified adverse event data for Stage 1 are provided in Supplementary Tables S10–S11. Table 2AEs in stage 15-dose Essen groupN = 394-dose Zagreb groupN = 40EventsnSubjectnPercent %EventsnSubjectnPercent%Overall adverse events452256.41502255.00Local and Systemic adverse reactions271641.03311742.50Injection-site pain10717.95191127.50Fever8410.269615.00Injection-site abnormal sensation337.69212.50Fatigue225.13112.50Injection-site discomfort225.13000.00Injection-site change color112.56000.00Injection-site pruritus112.56000.00Infectious and infective diseases337.69000.00Respiratory system, thoracic and mediastinal diseases737.698512.50Neurological diseases225.13337.50Limb discomfort437.69225.00Gastrointestinal system diseases225.13537.50Hypersensitivity reaction000.00112.5 AEs in stage 1 In stage 2, the total incidence of AEs was 35.17% in the Essen group, 36.50% in the control group and 30.00% in the Zagreb group, and grade 3 or higher AEs occurred in 1.17%, 0.50% and 1.17% respectively. The incidence rates of ARs were 28.50%, 31.67%, and 26.17% respectively. The severity was mainly grade 1. The constituent ratios of grade 1 were 79.45%, 81.68%, and 81.40% respectively; those of grade 2 were 18.71%, 17.67%, and 16.28% respectively, while those of grade 3 were 1.85%, 0.65%, and 2.33% respectively. No grade 4 or higher adverse events associated with the study vaccine were reported (Fig. 5). The incidences of total AEs and ARs in the 4-dose Zagreb group were significantly lower than those in the control group (PAEs = 0.0198, PARs = 0.0415), but not significantly different from the 5-dose Essen group (PAEs = 0.0646, PARs = 0.3998). The incidences of total AEs and ARs in the two 5-dose groups were similar, and there was no statistically significant difference(P AEs = 0.6735), PARs = 0.2572. Comparison of adverse events between the three groups in stage 2. Solicited systemic adverse reactions (A), solicited local reactions (B). Percentages of participants who had a solicited local or systemic adverse reaction within 7 days after each dose of vaccination The incidences of local ARs in the Essen, the control and the Zagreb group were 15.00%, 18.50% and 12.50% respectively. Among them, the incidence in the Zagreb group was significantly lower than that in the control group (p = 0.0051), but not significantly different from the Essen group (p = 0.2405). There was no significant difference between the 5-dose Essen group and the 5-dose control group (p = 0.1219). All three groups mainly presented with pain, fever and fatigue at the vaccination site. In terms of the frequency of ARs, the very common (at least 10%) ARs in three groups were all pain at the vaccination site. The common systemic reactions are fever, fatigue, headache, dizziness, myalgia, nausea and diarrhea. The common types of ARs in the two 5-dose groups were consistent. A total of 18 cases of SAEs were observed in three groups. Among them, there were 6(1.00%) cases in the 5-dose Essen group, 8(1.33%) cases in the 5-dose control group, 4(0.67%) cases in the 4-dose Zagreb group. All SAEs were judged by the researchers to be unrelated to the study vaccine (Table S12-13 in the Supplementary Material 1). Discussion In stage 2, a subset of subjects with no documented clinical history of rabies demonstrated seropositivity for rabies virus neutralizing antibodies. This observation can be plausibly explained by either an unrecorded prior vaccination or subclinical infection. The latter scenario posits that following exposure to a low viral inoculum or via non-biting routes of transmission (e.g., contact of saliva with minor skin breaches), an individual’s innate and early adaptive immune responses may successfully contain and clear the viral pathogen before it gains access to peripheral nerve endings. This abortive infection is sufficient to elicit a specific antibody response, resulting in seropositivity without progression to life-threatening neurological disease [20]. Critically, the phenomenon of subclinical infection underscores the fundamental principle of post-exposure prophylaxis (PEP). PEP effectively mimics and augments this natural defensive process by concurrently administering rabies immunoglobulins (passive immunity) and vaccine (active immunity), thereby providing critical protection before the virus can invade the central nervous system. China’s adoption of WHO-prequalified rabies vaccination regimens (Essen 5-dose and Zagreb 4-dose protocols) within national post-exposure prophylaxis guidelines has demonstrated optimal safety-efficacy profiles [21–23]. Accordingly, this study implemented both the Essen and Zagreb regimens in its experimental design, with satisfactory outcomes. In stage 2, no significant differences were observed in the incidence of ARs among the 5-dose groups. Compared with the Essen group, the Zagreb group exhibited a lower overall incidence of AEs, which was significantly reduced relative to the control group. This finding is consistent with the previous study and may be attributed to the lower total number of doses administered in the Zagreb regimen [24]. Injection site pain was one of the most frequently reported AEs. Common systemic AEs included fever and fatigue, aligning with outcomes from other clinical trials that employed both the Zagreb and Essen regimens [25, 26]. The majority of AEs were mild in severity (Grade 1). The incidence of Grade 3 AEs was relatively low, with no statistically significant difference between the two groups. Furthermore, no serious adverse events related to the vaccination were reported. After vaccination with the investigational vaccine in the 4-dose schedule and the 5-dose schedule respectively, the antibody GMCs and antibody seroconversion rates of the test vaccines in both schedules were not inferior to those in the 5-dose control group, and the 4-dose schedule of the test vaccine was also not inferior to the 5-dose schedule. This finding is consistent with earlier observations reported by Professor Li et al. [24]. Day-14 after the full immunization, all subjects exhibited antibody levels that complied with the standards set forth by the World Health Organization and the Chinese Pharmacopoeia, namely that the production efficacy of human rabies vaccines must be greater than 4.0 IU/mL [27]. This experiment also investigated immune persistence. The persistence observation results at 3 months and 12 months after the full vaccination course showed that both the 4-dose and 5-dose schedules of the investigational vaccine maintained a high antibody positive rate, which was similar to the study by Song Yun et al. [28]. The antibody GMC of the 4-dose schedule was lower than that of the 5-dose schedule. Moreover, there were no significant differences in the antibody positive rate and GMC at 12 months following the full vaccination course between the two 5-dose groups. This is the large-scale trial directly comparing MRC-5 and HDCV vaccines. However, this study also has some limitations. Firstly, children and the elderly were not included in the trial population in this study. Secondly, the population of this study is mainly of Han ethnicity, and the adaptability of other populations to the vaccine in this study needs to be considered. In conclusion, the phase III clinical trial verified that the freeze-dried human rabies vaccine (MRC-5 cells) exhibited safety and good tolerability post each dose and during follow-up. Being non-inferior to the positive control vaccine, it presents a fresh approach for rabies prophylaxis. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements The authors thank all investigators from the Hunan Provincial Center for Disease Control and Prevention, National Institutes for Food and Drug Control and Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. Abbreviations Human diploid cell vaccines The Rapid Fluorescence Focus Inhibition Test Adverse events Adverse reactions Serious adverse events Geometric Mean Concentration Post-exposure prophylaxis Authors’ contributions Lidong Gao, Xiaohong Wu, Shilong Yang and Lijuan Zhou designed the trial and contributed to critical review and revision of the manuscript. Xiaopan Chen and Lingfeng Yuan contributed to manuscript writing and manuscript revision. Danhua Zhao, Leitai Shi, Yunpeng Wang and Jia Li participated in the data interpretation and the drafting of the manuscript. Ping Wang was involved in conducting the statistical analysis. Junshi Zhao oversaw and participated in the on-site operations, encompassing participant recruitment, follow-up activities, and data gathering. All authors made contributions to the study and have reviewed and approved the final manuscript. Funding The work was supported by Anhui Zhifei Longcom Biopharmaceutical Co., Ltd, China. Data availability All data are available from the corresponding authors upon reasonable request. Declarations Ethics approval and consent to participate Ethics Committee of Hunan Provincial Center for Disease Control and Prevention has approved the experiment. The ethics approval number: IRB2019007. The ethics approval date: April 23, 2019. All protocols followed were consistent with the ethical guidelines set forth by the responsible bodies for human research (at both institutional and national levels) and aligned with the Helsinki Declaration. Prior to entering the study, each participant provided written, dated informed consent. Consent for publication Not applicable. Statement that our study adheres to CONSORT guidelines This study was conducted in accordance with the CONSORT guidelines, and the trial protocol was designed and implemented following the recommendations outlined in the latest version of the CONSORT statement. The manuscript has been prepared to comply with all relevant CONSORT criteria, ensuring transparent and comprehensive reporting of the trial design, methods, results, and conclusions. Competing interests Xiaopan Chen, Lingfeng Yuan, Ping Wang, Lijuan Zhou, and Shilong Yang are employees of Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., which produces the experimental vaccine evaluated in this study. The remaining authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Danhua Zhao, Junshi Zhao and Xiaopan Chen are contributed equally to this work. Contributor Information Xiaohong Wu, Email: wuxiaohong@nifdc.org.cn. Shilong Yang, Email: yangshilong@zhifeishengwu.com. Lidong Gao, Email: gldlj@hotmail.com. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement All data are available from the corresponding authors upon reasonable request.